Anatomy and Cell Biology

Michael J. Goodheart, MD

Portrait

Fellowship Director
Assistant Professor
Assistant Professor of Obstetrics and Gynecology  - Gynecologic Oncology
Assistant Professor of Anatomy and Cell Biology

Contact Information

Primary Office: 31508 PFP
200 Hawkins Dr
Iowa City, IA 52242
Phone: 319-356-2015

Email: michael-goodheart@uiowa.edu

Education

BA, Chemistry, North Carolina State University, Raleigh, North Carolina
BS, North Carolina State University, Raleigh, North Carolina
MD, Medicine, East Carolina State University School of Medicine, Greenville, North Carolina

Residency, Obstetrics and Gynecology, Louisiana State University School of Medicine, New Orleans, Louisiana
Residency, Surgery, University of South Florida School of Medicine, Tampa, Florida
Fellowship, Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa

Licensure and Certifications

Board Certified, Gynecologic Oncology, ABOG
General Obstetrics and Gynecology
Iowa Medical License, #33538

Research Summary

Relating p53 mutation types to angiogenesis and immunohistochemical expression in epithelial ovarian cancers, and mutations of the BRCA2 gene in ovarian cancers.

Transcriptional regulation of the lymphoid enhancer factor-1 (Lef-1) promoter and its relevance in the pathogenesis of ovarian and endometrial cancer.

All Publications

Salinas E, Dai D, Newtson A, McDonald M, Goodheart M, Leslie K, Gonzalez Bosquet J.  Pre-treatment Prediction Model in Endometrioid Andeocarcinoma of the Uterus Using Somatic Mutations.  Gynecol Onc.  2016 October. 143(1):215.

Guimarães-Young A, Neff T, Dupuy A, Goodheart M.  Conditional deletion of Sox17 reveals complex effects on uterine adenogenesis and function.  Dev Biol.  2016 June 15. 414(2):219-27.
[PubMed]

Dai D, Thiel K, Salinas E, Goodheart M, Leslie K, Gonzalez Bosquet J.  Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations [Epub ahead of print].  Gynecol Oncol.  2016 May 16. 
[PubMed]

Christensen D, Armaiz-Pena G, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart M, Bender D, Thacker P, Ahmed A, Penedo F, DeGeest K, Mendez L, Domann F, Sood A, Lutgendorf S.  SSRI use and clinical outcomes in epithelial ovarian cancer.  Oncotarget [Epub ahead of print].  2016 April 21. 
[PubMed]

Devor E, Schickling B, Reyes H, Warrier A, Lindsay B, Goodheart M, Santillan D, Leslie K.  Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.  Oncol Rep.  2016 April. 35(4):2461-5.
[PubMed]

Reyes H, Carlson M, Devor E, Zhang Y, Thiel K, Samuelson M, McDonald M, Yang S, Stephan J, Savage E, Dai D, Goodheart M, Leslie K.  Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.  Gynecol Oncol .  2016 January. 140(1):152-60.
[PubMed]

Davis L, Slavich G, Thacker P, Goodheart M, Bender D, Dahmoush L, Farley D, Markon K, Penedo E, Lubaroff D, Cole S, Sood A, Lutgendorf S.  Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer.  Cancer.  2015 October 1. 121(19):3543-50.
[PubMed]

Hansen J, Stephan J, Freesmeier M, Bender D, Button A, Goodheart M.  The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients. .  Gynecol Oncol.  2015 July. 138(1):154-8.
[PubMed]

Xie W, Fisher J, Lynch T, Luo M, Evans T, Neff T, Zhou W, Zhang Y, Ou Y, Bunnett N, Russo A, Goodheart M, Parekh K, Liu X, Engelhardt J.  CGRP induction in cystic fibrosis airways alters the submucosal gland progenitor cell niche in mice..  J Clin Invest.  2015 May. 125(5):2179.
[PubMed]

Schrepf A, Thaker P, Goodheart M, Bender D, Slavich G, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff D, Cole S, Sood A, Lutgendorf S.  Diurnal cortisol and survival in epithelial ovarian cancer.  Psychoneuroendocrinology.  2015 March. 563:256-67.
[PubMed]

Brachova P, Mueting S, Carlson M, Goodheart M, Button A, Mott S, Dai D, Thiel K, Devor E, Leslie K.  TP53 oncomorphic mutations predict resistence to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.  Int J Oncol.  2015 February. 46(2):607-18.
[PubMed]

Stephan J, Goodheart M, McDonald M, Hansen J, Reyes H,  A, Bender D.  Robotic surgery in super-morbidly obese patients with endometrial cancer.  Am J Obstet Gynecol.  2015 January 30. 
[PubMed]

Stephan J, McDonald M, Hansen J, Goodheart M.  Staging Endometrial Cancer.  CRSLS;  2014.  Available from: http://crsls.sls.org/2014-00246/

Stephan J, Hansen J, Samuelson M, McDonald M, Chin Y, Bender D, Reyes H, Button A, Goodheart M.  Intra-operative frozen section results reliably predict final pathology in endometrial cancer..  Gynecol Oncol. .  2014 June. 133(3):499-505.
[PubMed]

Zhang Z, Kim K, Li X, Moreno M, Sharp T, Goodheart M, Safe S, Dupuy A, Amendt B.  MicroRNA-26b Represses Colon Cancer Cell Proliferation by Inhibiting Lymphoid Enhancer Factor 1 (LEF-1) Expression.  Mol Cancer Ther .  2014 April 30. 13(7):1942-51.
[PubMed]

Xie W, Lynch T, Liu X, Tyler S, Yu S, Zhou X, Luo M, Kusner D, Sun X, Yi Y, Zhang Y, Goodheart M, Parekh K, Wells J, Xue H, Pevny L, Engelhardt J.  Sox2 modulates Lef-1 expression during airway submucosal gland development.  Am J Physiol Lung Cell Mol Physiol.  2014 April 1. 306(7):L645-60.
[PubMed]

Devor E, Reyes H, Santillan D, Santillan M, Onukwugha C, Goodheart M, Leslie K.  Placenta-specific protein 1: a potential key to many oncofetal-placental OB/GYN research questions..  Obstet Gynecol Int..  2014 March 17. 2014:5 pages.

Martin L, Sill M, Shahin M, Powell M, DiSilvestro P, Landrum L, Gaillard G, Goodheart M, Hoffman J, Schilder R.  A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.  Gynecol Oncol.  2014 March. 132(3):526-30.
[PubMed]

Lutgendorf S, Slavich G, Degeest K, Goodheart M, Bender D, Thacker P, Penedo F, Zimmerman B, Lucci 3rd J, Mendez L, Collins K, Sood A.  Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients.  Gynecol Oncol.  2013 December 13. 131(3):667-73.
[PubMed]

Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, Dahmoush L, Penedo F, Lucci 3rd J, Thacker P, Mendez L, Sood A, Slavich G, Lutgendorf S.  Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis..  Cancer.  2013 September 1. 119(17):3234-41.
[PubMed]

Nadkarni N, Geest K, Neff T, Young B, Bender D, Ahmed A, Smith B, Button A, Goodheart M.  Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer..  Cancer letters.  2013 April. 331(1):99-104.
[PubMed]

Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart M, Dahmoush L, Penedo F, Lucci J, Ganjei-Azar P, Mendez L, Markon K, Lubaroff D, Thaker P, Slavich G, Sood A, Lutgendorf S.  Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability..  Brain, behavior, and immunity.  2013 March. 30 Suppl:S126-34.
[PubMed]

Clevenger L, Schrepf A, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart M, Penedo F, Lubaroff D, Sood A, Lutgendorf S.  Sleep disturbance, cytokines, and fatigue in women with ovarian cancer..  Brain, behavior, and immunity.  2012 October. 26(7):1037-44.
[PubMed]

Engle D, Connor J, Morris P, Bender D, De Geest K, Ahmed A, Goodheart M.  Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial..  Archives of gynecology and obstetrics.  2012 September. 286(3):717-21.
[PubMed]

Abu-Hejleh T, Mezhir J, Goodheart M, Halfdanarson T.  Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers..  Current oncology reports.  2012 August. 14(4):277-84.
[PubMed]

Lutgendorf S, De Geest K, Bender D, Ahmed A, Goodheart M, Dahmoush L, Zimmerman M, Penedo F, Lucci J, Ganjei-Azar P, Thaker P, Mendez L, Lubaroff D, Slavich G, Cole S, Sood A.  Social influences on clinical outcomes of patients with ovarian cancer..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  2012 August. 30(23):2885-90.
[PubMed]

Shelton D, Fornalik H, Neff T, Park S, Bender D, DeGeest K, Liu X, Xie W, Meyerholz D, Engelhardt J, Goodheart M.  The role of LEF1 in endometrial gland formation and carcinogenesis..  PloS one.  2012 July 6. 7(7):e40312.
[PubMed]

Leslie K, Thiel K, Goodheart M, De Geest K, Jia Y, Yang S.  Endometrial cancer..  Obstetrics and gynecology clinics of North America.  2012 June. 39(2):255-68.
[PubMed]

Devor E, DE Mik J, Ramachandran S, Goodheart M, Leslie K.  Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma..  Experimental and therapeutic medicine.  2012 April. 3(4):677-682.
[PubMed]

Fornalik H, Goodheart M, Buekers T, De Geest K, Jacobson G.  Aspirin and Warfarin are associated with Improved Overall Survival in Medically Inoperable Endometrial Cancer Patients Treated with Radiation Therapy..  Gynecology & Obstetrics S4:002.  2012 January 25. 
[Link]

Shamshirsaz A, Buekers T, Degeest K, Bender D, Zamba G, Goodheart M.  A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival..  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.  2011 October. 21(7):1232-40.
[PubMed]

Devor E, Hovey A, Goodheart M, Ramachandran S, Leslie K.  microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs..  Oncology reports.  2011 October. 26(4):995-1002.
[PubMed]

Xie W, Fisher J, Lynch T, Luo M, Evans T, Neff T, Zhou W, Zhang Y, Ou Y, Bunnett N, Russo A, Goodheart M, Parekh K, Liu X, Engelhardt J.  CGRP induction in cystic fibrosis airways alters the submucosal gland progenitor cell niche in mice..  The Journal of clinical investigation.  2011 August. 121(8):3144-58.
[PubMed]

Zhang Z, Liu X, Wu T, Liu J, Zhang X, Yang X, Goodheart M, Engelhardt J, Wang Y.  Selective suppression of cervical cancer Hela cells by 2-O-β-D-glucopyranosyl-L-ascorbic acid isolated from the fruit of Lycium barbarum L..  Cell biology and toxicology.  2011 April. 27(2):107-21.
[PubMed]

Lutgendorf S, DeGeest K, Dahmoush L, Farley D, Penedo F, Bender D, Goodheart M, Buekers T, Mendez L, Krueger G, Clevenger L, Lubaroff D, Sood A, Cole S.  Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients..  Brain, behavior, and immunity.  2011 February. 25(2):250-5.
[PubMed]

Lutgendorf S, Mullen-Houser E, Russell D, Degeest K, Jacobson G, Hart L, Bender D, Anderson B, Buekers T, Goodheart M, Antoni M, Sood A, Lubaroff D.  Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach..  Brain, behavior, and immunity.  2010 November. 24(8):1231-40.
[PubMed]

Liu X, Luo M, Xie W, Wells J, Goodheart M, Engelhardt J.  Sox17 modulates Wnt3A/beta-catenin-mediated transcriptional activation of the Lef-1 promoter..  American journal of physiology. Lung cellular and molecular physiology.  2010 November. 299(5):L694-710.
[PubMed]

Steines J, Larson J, Wilkinson N, Kirby P, Goodheart M.  Intestinal lymphangiectasia mimicking primary peritoneal carcinoma..  American journal of obstetrics and gynecology.  2010 October. 203(4):e9-e11.
[PubMed]

Petersen E, Shamshirsaz A, Brennan T, Demetroulis E, Goodheart M.  Malignant pericardial effusion with cardiac tamponade in ovarian adenocarcinoma..  Archives of gynecology and obstetrics.  2009 October. 280(4):675-8.
[PubMed]

Goodheart M, Rose S, Hattermann-Zogg M, Smith B, De Young B, Buller R.  BRCA2 alteration is important in clear cell carcinoma of the ovary..  Clinical genetics.  2009 August. 76(2):161-7.
[PubMed]

Jacobson G, Lammli J, Zamba G, Hua L, Goodheart M.  Thromboembolic events in patients with cervical carcinoma: Incidence and effect on survival..  Gynecologic oncology.  2009 May. 113(2):240-4.
[PubMed]

Lutgendorf S, DeGeest K, Sung C, Arevalo J, Penedo F, Lucci J, Goodheart M, Lubaroff D, Farley D, Sood A, Cole S.  Depression, social support, and beta-adrenergic transcription control in human ovarian cancer..  Brain, behavior, and immunity.  2009 February. 23(2):176-83.
[PubMed]

Goodheart M, Jacobson G, Smith B, Zhou L.  Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity..  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.  2008 January. 18(1):95-103.
[PubMed]

Driskell R, Goodheart M, Neff T, Liu X, Luo M, Moothart C, Sigmund C, Hosokawa R, Chai Y, Engelhardt J.  Wnt3a regulates Lef-1 expression during airway submucosal gland morphogenesis..  Developmental biology.  2007 May. 305(1):90-102.
[PubMed]

Goodheart M, Ritchie J, Rose S, Fruehauf J, De Young B, Buller R.  The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer..  Clinical cancer research : an official journal of the American Association for Cancer Research.  2005 May. 11(10):3733-42.
[PubMed]

Jacobson G, Kamath R, Smith B, Goodheart M.  Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer..  Gynecologic oncology.  2005 February. 96(2):470-4.
[PubMed]

Geisler J, Goodheart M, Sood A, Holmes R, Hattermann-Zogg M, Buller R.  Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma..  Cancer.  2003 November. 98(10):2199-206.
[PubMed]

Rose S, Robertson A, Goodheart M, Smith B, DeYoung B, Buller R.  The impact of p53 protein core domain structural alteration on ovarian cancer survival..  Clinical cancer research : an official journal of the American Association for Cancer Research.  2003 September. 9(11):4139-44.
[PubMed]

Stone P, Goodheart M, Rose S, Smith B, DeYoung B, Buller R.  The influence of microvessel density on ovarian carcinogenesis..  Gynecologic oncology.  2003 September. 90(3):566-71.
[PubMed]

Rose S, Goodheart M, DeYoung B, Smith B, Buller R.  p21 expression predicts outcome in p53-null ovarian carcinoma..  Clinical cancer research : an official journal of the American Association for Cancer Research.  2003 March. 9(3):1028-32.
[PubMed]

Goodheart M, Vasef M, Sood A, Davis C, Buller R.  Ovarian cancer p53 mutation is associated with tumor microvessel density..  Gynecologic oncology.  2002 July. 86(1):85-90.
[PubMed]

Date Last Modified: 06/06/2016 - 13:17:48